0001104659-24-034670.txt : 20240314 0001104659-24-034670.hdr.sgml : 20240314 20240314205123 ACCESSION NUMBER: 0001104659-24-034670 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240313 FILED AS OF DATE: 20240314 DATE AS OF CHANGE: 20240314 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Gilad Oren CENTRAL INDEX KEY: 0001929300 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39069 FILM NUMBER: 24752206 MAIL ADDRESS: STREET 1: 535 BOYLSTON STREET CITY: BOSTON STATE: MA ZIP: 02116 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Aprea Therapeutics, Inc. CENTRAL INDEX KEY: 0001781983 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 3805 OLD EASTON ROAD CITY: DOYLESTOWN STATE: PA ZIP: 18902 BUSINESS PHONE: 617-463-9385 MAIL ADDRESS: STREET 1: 3805 OLD EASTON ROAD CITY: DOYLESTOWN STATE: PA ZIP: 18902 4 1 tm248935-1_4seq1.xml OWNERSHIP DOCUMENT X0508 4 2024-03-13 0 0001781983 Aprea Therapeutics, Inc. APRE 0001929300 Gilad Oren 3805 OLD EASTON ROAD DOYLESTOWN PA 18902 1 1 0 0 President, CEO 0 Common Stock 2024-03-13 4 P 0 2000 7.29 A 324770 D Tranche A Warrant 2024-03-13 4 P 0 1000 A 2024-03-13 Common Stock 1000 1000 D Tranche B Warrant 2024-03-13 4 P 0 1000 A 2024-03-13 Common Stock 1000 1000 D The exercise price of the Tranche A Warrants is as follows: 1,000 shares of the Company's common stock at the exercise price of $7.29 per share or warrants for an exercise price of $7.29 minus $0.001 per share. Tranche A Warrants shall expire on March 13, 2027; provided, however, that (A) if (i) the Company publicly announces, the recommended Phase 2 dose for ATRN-119, and (ii) the daily VWAP of the Common Stock equals or exceeds $14.58 per share for any 30 consecutive Trading Day period commencing on or after the Trading Day on which the announcement was made, then the Termination Date shall be 30 days following the date on which both (i) and (ii) above have occurred. The purchase price for the Tranche A Warrants is included in the purchase price for the shares of Common Stock reflected in Table I above. The exercise price of the Tranche B Warrants is as follows: 1,000 shares of the Company's common stock at the exercise price of $9.1125 per share or warrants for an exercise price of $9.1125 minus $0.001 per share. Tranche B Warrants shall expire on March 13, 2029; provided, however, that (A) if (i) the Company publicly announces, the recommended Phase 2 dose for APR-1051, and (ii) the daily VWAP of the Common Stock equals or exceeds $18.225 per share for any 30 consecutive Trading Day period commencing on or after the Trading Day on which the announcement was made, then the Termination Date shall be 30 days following the date on which both (i) and (ii) above have occurred. The purchase price for the Tranche B Warrants is included in the purchase price for the shares of Common Stock reflected in Table I above. /s/ John Hamill, as Attorney-in-Fact 2024-03-14